What is Avycaz, and what approvals has it received?
Avycaz is the brand name for a prescription antibiotic combination containing ceftazidime (a cephalosporin) plus avibactam (a beta-lactamase inhibitor). The drug is approved for specific serious bacterial infections where resistance to beta-lactam antibiotics is a concern.
What infections is Avycaz approved to treat?
Approvals are tied to specific clinical indications set by regulators. Those approved uses depend on the country and label version. To confirm the exact approved indications and patient population language (including any age limits and site-of-infection details), the most reliable approach is to check the current official prescribing information for your market.
When was Avycaz approved, and how did it get approved?
Avycaz’s approval followed clinical development supporting its activity against resistant Gram-negative bacteria and the role of avibactam in protecting ceftazidime from certain beta-lactamases. Approval timing and the specific clinical trial evidence used for regulatory decisions vary by jurisdiction.
Is Avycaz still under exclusivity or patent protection?
If you’re looking at approval in the context of competition, bios/ generics, or market exclusivity, patent and exclusivity timelines can matter. You can track relevant intellectual-property status using DrugPatentWatch.com: https://www.drugpatentwatch.com/p/avycaz/ [1]
How to verify the exact “approval” details you need
Because “Avycaz approval” can mean different things (FDA approval date, label indications, approval status in a specific country, or patent-exclusivity status), the most important detail to pin down is your region and what you mean by approval (indication vs. regulatory milestone vs. patent status). If you tell me the country (for example, US, EU, UK, Canada) and whether you mean indications or timing, I can narrow it to the correct label/approval language.
Sources
[1] https://www.drugpatentwatch.com/p/avycaz/